Novel approaches to assessing upper motor neuron dysfunction in motor neuron disease/amyotrophic lateral sclerosis: IFCN handbook chapter.

Amyotrophic lateral sclerosis Cortical hyperexcitability Diffusion tensor imaging Functional MRI Magnetic resonance spectroscopy Motor neuron disease Positron emission tomography Short interval intracortical inhibition Transcranial magnetic stimulation

Journal

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
ISSN: 1872-8952
Titre abrégé: Clin Neurophysiol
Pays: Netherlands
ID NLM: 100883319

Informations de publication

Date de publication:
18 Apr 2024
Historique:
received: 01 10 2023
revised: 08 02 2024
accepted: 14 04 2024
medline: 6 5 2024
pubmed: 6 5 2024
entrez: 5 5 2024
Statut: aheadofprint

Résumé

Identifying upper motor neuron (UMN) dysfunction is fundamental to the diagnosis and understanding of disease pathogenesis in motor neuron disease (MND). The clinical assessment of UMN dysfunction may be difficult, particularly in the setting of severe muscle weakness. From a physiological perspective, transcranial magnetic stimulation (TMS) techniques provide objective biomarkers of UMN dysfunction in MND and may also be useful to interrogate cortical and network function. Single, paired- and triple pulse TMS techniques have yielded novel diagnostic and prognostic biomarkers in MND, and have provided important pathogenic insights, particularly pertaining to site of disease onset. Cortical hyperexcitability, as heralded by reduced short interval intracortical inhibition (SICI) and increased short interval intracortical facilitation, has been associated with the onset of lower motor neuron degeneration, along with patterns of disease spread, development of specific clinical features such as the split hand phenomenon, and may provide an indication about the rate of disease progression. Additionally, reduction of SICI has emerged as a potential diagnostic aid in MND. The triple stimulation technique (TST) was shown to enhance the diagnostic utility of conventional TMS measures in detecting UMN dysfunction in MND. Separately, sophisticated brain imaging techniques have uncovered novel biomarkers of neurodegeneration that have bene associated with progression. The present review will discuss the utility of TMS and brain neuroimaging derived biomarkers of UMN dysfunction in MND, focusing on recently developed TMS techniques and advanced neuroimaging modalities that interrogate structural and functional integrity of the corticomotoneuronal system, with an emphasis on pathogenic, diagnostic, and prognostic utility.

Identifiants

pubmed: 38705104
pii: S1388-2457(24)00127-5
doi: 10.1016/j.clinph.2024.04.010
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

68-89

Informations de copyright

Copyright © 2024 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.

Auteurs

Thanuja Dharmadasa (T)

Department of Neurology, The Royal Melbourne Hospital City Campus, Parkville, Victoria, Australia.

Nathan Pavey (N)

Brain and Nerve Research Center, The University of Sydney, Sydney, Australia.

Sicong Tu (S)

Brain and Mind Centre, The University of Sydney, and Department of Neurology, Royal Prince Alfred Hospital, Australia.

Parvathi Menon (P)

Brain and Nerve Research Center, The University of Sydney, Sydney, Australia.

William Huynh (W)

Brain and Mind Centre, The University of Sydney, and Department of Neurology, Royal Prince Alfred Hospital, Australia.

Colin J Mahoney (CJ)

Brain and Mind Centre, The University of Sydney, and Department of Neurology, Royal Prince Alfred Hospital, Australia.

Hannah C Timmins (HC)

Brain and Mind Centre, The University of Sydney, and Department of Neurology, Royal Prince Alfred Hospital, Australia.

Mana Higashihara (M)

Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.

Mehdi van den Bos (M)

Brain and Nerve Research Center, The University of Sydney, Sydney, Australia.

Kazumoto Shibuya (K)

Neurology, Chiba University, Graduate School of Medicine, Chiba, Japan.

Satoshi Kuwabara (S)

Neurology, Chiba University, Graduate School of Medicine, Chiba, Japan.

Julian Grosskreutz (J)

Precision Neurology, Excellence Cluster Precision Medicine in Inflammation, University of Lübeck, University Hospital Schleswig-Holstein Campus, Lübeck, Germany.

Matthew C Kiernan (MC)

Brain and Mind Centre, The University of Sydney, and Department of Neurology, Royal Prince Alfred Hospital, Australia.

Steve Vucic (S)

Brain and Nerve Research Center, The University of Sydney, Sydney, Australia. Electronic address: steve.vucic@sydney.edu.au.

Classifications MeSH